Many liver diseases are associated with endocrine disorders, including nonalcoholic fatty liver disease (NAFLD), autoimmune hepatitis and primary biliary cirrhosis. NAFLD is the most common liver disorder worldwide and its rising prevalence mirrors that of obesity and type 2 diabetes. Thyroid disorders are often associated with hepatic alterations. Chronic liver disease can impair menstruation and fertility. In addition, patients with diabetes have a higher prevalence of significant liver fibrosis and enhanced risk of disease progression to cirrhosis and hepatocellular carcinoma. Management of these disorders should consider the relationship between the liver and the endocrine system, in order to address all manifestations and complications.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Liver Disorders Content
Non-alcoholic Steatohepatitis: From Pathophysiology to Clinical Practice
touchREVIEWS in Endocrinology. 2021;1(2):Online ahead of journal publication
Non-alcoholic fatty liver disease (NAFLD) consists of non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). It is unclear which specific patients progress from NAFL to NASH and, ultimately, to cirrhosis. However, there is general consensus that, for those patients who do progress to cirrhosis (fibrosis stage 4), there is an increased risk of liver-related complications […]
Luca Valenti, NAFLD Summit 2021: The Latest Advances in NAFLD
TouchENDOCRINOLOGY joins Prof Luca Valenti (University of Milan, Italy) at the Digital NAFLD Summit 2021 to discuss his hopes for the conference and the most exciting new developments in the field of non-alcoholic fatty liver disease (NAFLD). Questions Could you give us an overview of the clinical spectrum of non-alcoholic fatty liver disease (NAFLD) and […]
Rohit Loomba, EASL ILC 2021: Pemafibrate Phase 2 Results in NAFLD
We continue our discussion with Prof. Rohit Loomba (University of California, San Diego, CA, USA) by exploring the results for the phase 2 study investigating pemafibrate in NAFLD. Part 1 of our video interview can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARM alpha), improves liver stiffness […]
Rohit Loomba, EASL ILC 2021: Rationale for Pemafibrate in NAFLD
It was a pleasure to speak with Prof. Rohit Loomba (University of California, San Diego, CA, USA) about the rationale for the use of the novel SPPARM inhibitor, pemafibrate, in the treatment of NAFLD. Part 2 of our discussion can be found here. His presentation entitled ‘Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator […]
Sven Francque, EASL ILC 2021: Lanifibranor NATIVE Subgroup Analysis
Prof. Dr Sven Francque (University of Antwerp, Belgium) kindly spoke with us about the additional analysis of the phase 2b NATIVE trial investigating lanifibranor in patients with NASH. His presentation entitled ‘Lanifibranor therapy improves markers of lipid metabolism, insulin resistance, liver injury and fibrosis in patients with NASH and F2 and F3 fibrosis stages: a […]
Sven Francque, EASL ILC 2021: Subgroup Analysis of Semaglutide in NASH
It was a pleasure to speak with Prof. Dr Sven Francque (University of Antwerp, Belgium) about the recent post-hoc analysis of the phase 2 trial of semaglutide in patients with NASH. The analysis was designed to assess whether patient and disease characteristics influenced the effect of the drug on the resolution of NASH. His abstract […]
Kenneth Cusi, EASL ILC 2021: First-in-class AMP-Kinase Activator, PXL770, in NASH
It was an absolute pleasure to speak with Dr Kenneth Cusi (University of Florida, Gainesville, FL, USA) about the novel compound PXL770 and the results of the STAMP-NAFLD phase 2 trial investigating its potential in NASH. His abstract entitled ‘Human proof-of-concept in non-alcoholic liver disease (NAFLD) patients with PXL770, a novel first-in-class direct AMP-kinase activator […]
Arun Sanyal, EASL ILC 2021: Icosabutate ICONA Trial in NASH
In Part 2, we speak with Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) about the interim analysis from the ICONA trial (NCT04052516) which is designed to investigate icosabutate as a potential therapeutic approach to address liver- and cardiovascular-related morbidity and mortality in patients with NASH. His abstract entitled ‘Icosabutate, a novel structurally engineered […]
Arun Sanyal, EASL ILC 2021: Icosabutate Mechanism of Action
In Part 1, Prof. Arun Sanyal (Virginia Commonwealth University, Richmond, VA, USA) speaks to us about the mechanism of action of icosabutate, a novel engineered fatty acid currently under investigation in NASH. He continues this conversation in Part 2 where we discuss the results from the interim analysis of the ICONA trial (NCT04052516). His abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!